Immunization, Vaccines and Biologicals

SAGE Working Group on pertussis vaccines (July 2009 to October 2010)

Terms of Reference

Review the evidence and prepare for a SAGE review of the impact of current vaccination strategy and surveillance efforts in support of current control efforts.

Propose necessary updating of current control goals, recommendations on vaccine use (as stated in the current (2005) pertussis vaccine position paper), and surveillance strategies and effort and identify important information gaps.

The specific questions/issues will be given attention:

  • Surveillance, burden. and impact
    • Impact of current vaccination strategies and level of implementation
    • Vaccine effectiveness against mortality and other clinical outcomes
    • Appropriateness of current parameters used in burden estimates
    • Effectiveness of current pertussis surveillance efforts
  • Primary immunization schedule
    • Optimal primary schedule
    • Is there still a need to promote immunization at 6 weeks?
  • Supplementary vaccine activities
    • Need and timing of booster dose(s)
    • Role of vaccination of adolescents and adults
    • Optimal strategy to prevent early infant deaths including role of vaccination of parents in disease prevention in neonates
    • Response to periodic epidemics
  • Vaccine issues
    • Respective advantages of wP and aP vaccines (including safety profile)
    • Interchange-ability of vaccines
    • Combined vaccines
    • Co-administration


SAGE Members

  • Zulfiqar Bhutta
  • David Durrheim
  • Elizabeth Miller, Chair


  • Rose-Marie Carlsson, Swedish Armed Forces, Sweden
  • Joyce Ducusin, Department of Health, Philippines
  • Kathryn Edwards, Vanderbilt University, USA
  • Nicole Guiso, Institut Pasteur, France
  • Scott Halperin, Dalhousie University, Canada
  • Stacey Martin, Centers for Disease Control and Prevention, USA
  • Peter McIntyre, University of Sydney, Australia
  • James Southern, South Africa and Chair Developing Country Vaccine Regulatory Network, South Africa
  • Carl H. Wirsing von König, Klinikum Krefeld, Germany

WHO Secretariat

  • Philippe Duclos
  • Ana-Maria Henao-Restrepo
  • Jose Mauricio Landaverde
  • Peter Strebel


All members completed a declaration of interest. In total six members reported relevant interests.

Dr Rose-Marie Carlsson reported that:

• Until recently she led a national pertussis surveillance project, which was partially funded by GlaxoSmithKline, Sanofi Pasteur and Sanofi Pasteur MSD.

Prof Kathryn Edwards reported that:

• Her laboratory received funding from Sanofi Pasteur to perform pertussis laboratory assays.

Dr Nicole Guiso reported that:

• She is involved in training for health care workers for Sanofi Pasteur and GlaxoSmithKline and received via Institut Pasteur a small remuneration for this.
• Her laboratory has a research-development contract with GlaxoSmithKline and receives funding to determine the incidence of pertussis in adults from Sanofi Pasteur and GlaxoSmithKline.

Prof Scott Halperin reported that:

• His Centre has received multiple contracts and grants from Sanofi Pasteur and GlaxoSmithKline for clinical trials related to pertussis vaccines. His Centre has also received small education grants to support the attendance of nurse coordinators at scientific meetings.
• He participated in Ad Hoc advisory boards for Sanofi Pasteur and GlaxoSmithKline.

Prof Peter McIntyre reported that:

• His department has received in-kind support from GlaxoSmithKline in the context of a neonatal pertussis vaccine trial sponsored by the Health and Medical Research Council of Australia.

Prof Carl H. Wirsing von König reported that:

• He participated in scientific advisory boards for GlaxoSmithKline and Sanofi Pasteur MSD.
• His Institut has received grants from GlaxoSmithKline and Sanofi Pasteur MSD for epidemiological studies.

Last updated: 8 October 2010